日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Long-term quality of life in non-epithelial ovarian cancer survivors: TMRG-GINECO-Vivrovaire rare tumors case-control study

非上皮性卵巢癌幸存者的长期生活质量:TMRG-GINECO-Vivrovaire罕见肿瘤病例对照研究

Dubot, Coraline; Ray-Coquard, Isabelle; Lequesne, Justine; Pautier, Patricia; Renaud, Tiphaine; Selle, Frédéric; Berton-Rigaud, Dominique; Frank, Sophie; De La Motte Rouge, Thibault; Kalbacher, Elsa; Provansal, Magali; Blonz, Cyriac; Orfeuvre, Hubert; Alexandre, Jérôme; Augereau, Paule; Nadeau, Cédric; Kurtz, Jean-Emmanuel; Hanvic, Brunhilde; Fresneau, Brice; Ahmed-Lecheheb, Djihane; Christy, François; Grellard, Jean-Michel; Clarisse, Bénédicte; Gernier, François; Joly, Florence

Addressing screening failures in early-phase clinical trials in oncology: impact on patient outcomes and strategies for improvement

解决肿瘤早期临床试验中筛选失败的问题:对患者预后的影响及改进策略

Korakis, I; Ouali, K; Hanvic, B; Verlingue, L; Allignet, B; Lusque, A; Clementei, S; Magne, E; Massard, C; Delord, J-P; Cassier, P; Baldini, C; Segier, B; Gomez-Roca, C

Efficacy of chemotherapy after progression during or following PARPi exposure in ovarian cancer

卵巢癌患者在接受PARP抑制剂治疗期间或之后病情进展时化疗的疗效

Xu-Vuillard, A; Guerin-Charbonnel, C; Bocquet, F; Cheeseman, S; Kubelac, P M; Zenatri, M; Hall, G; Achimas-Cadariu, P; Hanvic, B; Fenton, H; Sturz-Lazăr, A-M-L; Augereau, P; Ray-Coquard, I; Leary, A; Frenel, J-S

BRCA1/2 alterations and reversion mutations in the area of PARP inhibitors in high grade ovarian cancer: state of the art and forthcoming challenges

BRCA1/2 改变和 PARP 抑制剂治疗高级别卵巢癌的回复突变:现状与未来挑战

Collet, Laetitia; Hanvic, Brunhilde; Turinetto, Margherita; Treilleux, Isabelle; Chopin, Nicolas; Le Saux, Olivia; Ray-Coquard, Isabelle